Second dose of targeted radiation shows promise for tough prostate cancer
NCT ID NCT06288113
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving a second round of a radioactive drug called 177Lu-PSMA-617 can help men with advanced prostate cancer that no longer responds to hormone therapy. The drug targets and delivers radiation directly to cancer cells. Participants must have already had a good response to their first round of this treatment. The goal is to see if re-treatment can improve survival and control the disease longer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90095, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a three-drug cocktail outsmart resistant prostate cancer?
- Precision radiation may tame rising PSA after prostate surgery
- Blood test could tell doctors when to stop prostate cancer treatment early
- Could a stronger first dose of targeted radiation beat back advanced prostate cancer?
- Targeted radiation plus hormone therapy may slow Low-Volume prostate cancer spread